Showing 111 - 120 of 36,512
Objective: The first aim was to identify and determine the economic costs of the regimens currently used in 3 New Zealand hospitals in the treatment of bacterial infections in haematology patients with febrile neutropenia and in intensive care patients with severe infections. The second was to...
Persistent link: https://www.econbiz.de/10005590387
Background: Limited information exists on the best way to organise stroke rehabilitation after hospital discharge and the relative costs of such services. Objective: To review the evidence of the cost effectiveness of services that accelerate hospital discharge and provide home-based...
Persistent link: https://www.econbiz.de/10005590399
Objective: Osteoporosis-related costs are now considered a major burden for health authorities in most developed countries. An accurate and exhaustive evaluation of these costs would be a major contribution to health economic studies evaluating the efficiency of screening and prevention...
Persistent link: https://www.econbiz.de/10005590407
of the pump and related hospitalisation days. The total costs of patient selection, testing, implanting the pump and …) can be attributed mostly to implantation of the pump and related hospitalisation days. Savings originated from withdrawal …
Persistent link: https://www.econbiz.de/10005590444
Objective: To investigate whether the extent of systolic dysfunction is a useful predictor of the costs of healthcare and social support for patients with heart failure. Design: Cross-sectional study with collection of cost data attributed to management of heart failure in the previous year....
Persistent link: https://www.econbiz.de/10005590477
The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different aetiologies, administration of the beta1-adrenoceptor blocker bisoprolol as an adjuvant to the standard therapy leads to a significant avoidance of hospital admissions. A...
Persistent link: https://www.econbiz.de/10005590513
Background:Background: Rasburicase is a recombinant urate-oxidase enzyme used to reduce high levels of plasma uric acid (PUA) resulting from tumour lysis syndrome (TLS). Rasburicase reduces PUA levels within 4 hours of administration, thereby minimizing the risk of serious complications from...
Persistent link: https://www.econbiz.de/10010585887
Diabetic retinopathy is a significant cause of visual loss in developed countries. Data from epidemiological studies and controlled clinical trials have resulted in treatment strategies, which are highly successful in preventing blindness. These strategies involve measures that require both...
Persistent link: https://www.econbiz.de/10005243003
Osteoporosis constitutes a major public health problem through its association with fractures at several skeletal sites, most notably the hip, wrist and vertebra. The lifetime risk of hip fracture in White women and men in the UK from age 50 years is 14% and 3%, respectively. These fractures...
Persistent link: https://www.econbiz.de/10005243023
In an effort to improve patient outcomes and reduce resource use and costs associated with asthma care, asthma disease management programmes have now gained momentum. If a programme is to be effective, the identification of goals and outcomes relevant to the target populations is essential....
Persistent link: https://www.econbiz.de/10005243027